Zacks Investment Management Sells 9,152 Shares of Stryker Co. (NYSE:SYK)

Zacks Investment Management cut its holdings in Stryker Co. (NYSE:SYK - Free Report) by 12.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 67,117 shares of the medical technology company's stock after selling 9,152 shares during the quarter. Zacks Investment Management's holdings in Stryker were worth $24,165,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Stryker during the 4th quarter worth approximately $25,000. Rakuten Securities Inc. boosted its stake in Stryker by 618.2% during the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock worth $28,000 after acquiring an additional 68 shares during the last quarter. Centricity Wealth Management LLC bought a new position in shares of Stryker during the fourth quarter worth $30,000. BankPlus Trust Department bought a new position in Stryker during the fourth quarter worth about $33,000. Finally, Activest Wealth Management bought a new position in shares of Stryker during the 4th quarter valued at about $36,000. 77.09% of the stock is owned by institutional investors.

Stryker Stock Performance

SYK traded up $6.09 during trading on Tuesday, hitting $345.68. The stock had a trading volume of 309,521 shares, compared to its average volume of 1,353,468. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The firm has a market cap of $131.94 billion, a price-to-earnings ratio of 44.55, a P/E/G ratio of 2.93 and a beta of 0.93. The company has a 50 day moving average price of $370.04 and a 200-day moving average price of $373.23.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the previous year, the business posted $3.46 earnings per share. As a group, research analysts predict that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.97%. The ex-dividend date is Monday, March 31st. Stryker's dividend payout ratio (DPR) is presently 43.30%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. JMP Securities restated a "market perform" rating on shares of Stryker in a report on Tuesday, February 18th. The Goldman Sachs Group set a $422.00 price target on shares of Stryker in a research note on Tuesday, March 4th. Argus set a $450.00 price objective on shares of Stryker in a research report on Monday, February 3rd. Wells Fargo & Company raised their target price on shares of Stryker from $427.00 to $435.00 and gave the company an "overweight" rating in a research report on Wednesday, January 29th. Finally, Royal Bank of Canada boosted their price target on shares of Stryker from $425.00 to $435.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Stryker currently has a consensus rating of "Moderate Buy" and an average price target of $423.53.

Insider Buying and Selling at Stryker

In related news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now directly owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the firm's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.